These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 9576457)
1. Significance of diminished factor XIII in Crohn's disease. Chamouard P; Grunebaum L; Wiesel ML; Sibilia J; Coumaros G; Wittersheim C; Baumann R; Cazenave JP Am J Gastroenterol; 1998 Apr; 93(4):610-4. PubMed ID: 9576457 [TBL] [Abstract][Full Text] [Related]
2. Deficiency of blood coagulation factor XIII in Crohn's disease. Oshitani N; Kitano A; Hara J; Suzuki N; Aoki T; Yasuda K; Watanabe Y; Obayashi M; Obata A; Nakamura S Am J Gastroenterol; 1995 Jul; 90(7):1116-8. PubMed ID: 7611208 [TBL] [Abstract][Full Text] [Related]
3. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Niederau C; Backmerhoff F; Schumacher B; Niederau C Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126 [TBL] [Abstract][Full Text] [Related]
4. Clinical significance of measuring blood coagulation factor XIIIA regularly and continuously in patients with Crohn's disease. Higaki S; Nakano K; Onaka S; Amano A; Tanioka Y; Harada K; Hashimoto S; Sakaida I; Okita K J Gastroenterol Hepatol; 2006 Sep; 21(9):1407-11. PubMed ID: 16911684 [TBL] [Abstract][Full Text] [Related]
5. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B; Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104 [TBL] [Abstract][Full Text] [Related]
6. Kallikrein-kinin system activation in Crohn's disease: differences in intestinal and systemic markers. Devani M; Cugno M; Vecchi M; Ferrero S; Di Berardino F; Avesani EC; de Franchis R; Colman RW Am J Gastroenterol; 2002 Aug; 97(8):2026-32. PubMed ID: 12190172 [TBL] [Abstract][Full Text] [Related]
7. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease. Gao Q; Hogezand RA; Lamers CB; Verspaget HW Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330 [TBL] [Abstract][Full Text] [Related]
8. Plasma levels of endothelin-1 in patients with Crohn's disease and ulcerative colitis. Letizia C; Boirivant M; De Toma G; Cerci S; Subioli S; Scuro L; Ferrari P; Pallone F Ital J Gastroenterol Hepatol; 1998 Jun; 30(3):266-9. PubMed ID: 9759593 [TBL] [Abstract][Full Text] [Related]
9. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192 [TBL] [Abstract][Full Text] [Related]
10. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features. Annese V; Piepoli A; Perri F; Lombardi G; Latiano A; Napolitano G; Corritore G; Vandewalle P; Poulain D; Colombel JF; Andriulli A Aliment Pharmacol Ther; 2004 Nov; 20(10):1143-52. PubMed ID: 15569117 [TBL] [Abstract][Full Text] [Related]
11. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Dotan I; Fishman S; Dgani Y; Schwartz M; Karban A; Lerner A; Weishauss O; Spector L; Shtevi A; Altstock RT; Dotan N; Halpern Z Gastroenterology; 2006 Aug; 131(2):366-78. PubMed ID: 16890590 [TBL] [Abstract][Full Text] [Related]
12. [Value of C-reactive protein in the evaluation of activity in ulcerative colitis and Crohn's disease]. Vucelić B; Krznarić Z; Sentić M; Milicić D; Korać B; Cvorisćec D; Stavljenić A Lijec Vjesn; 1990; 112(9-10):281-4. PubMed ID: 2093781 [TBL] [Abstract][Full Text] [Related]
13. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Folwaczny C; Wiebecke B; Loeschke K Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease. Griga T; May B; Pfisterer O; Müller KM; Brasch F Hepatogastroenterology; 2002; 49(43):116-23. PubMed ID: 11941933 [TBL] [Abstract][Full Text] [Related]
15. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Kanazawa S; Tsunoda T; Onuma E; Majima T; Kagiyama M; Kikuchi K Am J Gastroenterol; 2001 Mar; 96(3):822-8. PubMed ID: 11280558 [TBL] [Abstract][Full Text] [Related]
16. Identification of a prodromal period in Crohn's disease but not ulcerative colitis. Pimentel M; Chang M; Chow EJ; Tabibzadeh S; Kirit-Kiriak V; Targan SR; Lin HC Am J Gastroenterol; 2000 Dec; 95(12):3458-62. PubMed ID: 11151877 [TBL] [Abstract][Full Text] [Related]
17. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission. Valentini L; Schaper L; Buning C; Hengstermann S; Koernicke T; Tillinger W; Guglielmi FW; Norman K; Buhner S; Ockenga J; Pirlich M; Lochs H Nutrition; 2008; 24(7-8):694-702. PubMed ID: 18499398 [TBL] [Abstract][Full Text] [Related]
18. Determination of prothrombin activation fragments in young patients with inflammatory bowel disease. Smith CJ; Haire WD; Kaufman SS; Mack DR Am J Gastroenterol; 1996 Jun; 91(6):1221-5. PubMed ID: 8651175 [TBL] [Abstract][Full Text] [Related]
19. Coagulation studies in ulcerative colitis and Crohn's disease. Lam A; Borda IT; Inwood MJ; Thomson S Gastroenterology; 1975 Feb; 68(2):245-51. PubMed ID: 1116673 [TBL] [Abstract][Full Text] [Related]
20. [The usefulness of reactive protein C in managing patients with ulcerative colitis and Crohn's disease]. López Morante AJ; Sáez-Royuela F; Yuguero del Moral L; Martín Lorente JL; Ojeda Giménez C Rev Esp Enferm Dig; 1993 Jan; 83(1):5-9. PubMed ID: 8452705 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]